Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study

Authors:

Abstract
No abstract available
Funding Information
  • Amicus Therapeutics

This publication has 40 references indexed in Scilit: